Repligen Co. (NASDAQ:RGEN) Shares Sold by Geneva Capital Management LLC

Geneva Capital Management LLC lowered its position in shares of Repligen Co. (NASDAQ:RGEN) by 1.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 118,718 shares of the biotechnology company’s stock after selling 1,449 shares during the quarter. Geneva Capital Management LLC’s holdings in Repligen were worth $21,835,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Repligen by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 5,078,294 shares of the biotechnology company’s stock valued at $913,077,000 after purchasing an additional 33,404 shares in the last quarter. Brown Capital Management LLC increased its holdings in shares of Repligen by 5.8% in the fourth quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock valued at $274,207,000 after buying an additional 83,416 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Repligen by 2.1% during the 3rd quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock valued at $222,075,000 after acquiring an additional 29,215 shares during the last quarter. Conestoga Capital Advisors LLC boosted its stake in shares of Repligen by 5.3% during the 1st quarter. Conestoga Capital Advisors LLC now owns 747,555 shares of the biotechnology company’s stock worth $137,490,000 after acquiring an additional 37,817 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of Repligen by 31.5% in the 1st quarter. Principal Financial Group Inc. now owns 345,445 shares of the biotechnology company’s stock worth $63,534,000 after acquiring an additional 82,737 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Activity

In other Repligen news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the sale, the chief executive officer now owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Martin D. Madaus bought 1,615 shares of the stock in a transaction on Friday, June 14th. The shares were acquired at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the transaction, the director now directly owns 4,613 shares of the company’s stock, valued at $576,348.22. The disclosure for this purchase can be found here. 1.20% of the stock is owned by corporate insiders.

Repligen Stock Up 4.3 %

RGEN stock traded up $5.22 during midday trading on Thursday, reaching $126.17. The company had a trading volume of 633,978 shares, compared to its average volume of 596,097. The company has a 50 day moving average of $144.69 and a two-hundred day moving average of $170.63. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The company has a market capitalization of $7.05 billion, a P/E ratio of 505.02, a PEG ratio of 4.01 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter in the prior year, the business posted $0.64 earnings per share. Repligen’s revenue was down 17.1% on a year-over-year basis. On average, equities research analysts expect that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on RGEN. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and decreased their price target for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. JPMorgan Chase & Co. decreased their target price on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Finally, Guggenheim started coverage on shares of Repligen in a report on Tuesday, June 18th. They set a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average target price of $193.00.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.